Merck To Acquire Tilos Therapeutics for ~ $773M
Shots:
- Merck acquires Tilos Therapeutics- in all-stock transaction. Tilos Therapeutics to receive upfront and contingent milestone payments- making the total deal value ~$773M
- The focus of the acquisition is to strengthen Merck’s footprint with the addition of Tilos’ antibodies modulating TGFβ portfolio targeting cancer- fibrosis and autoimmune diseases
- TGFβ is a cytokine secreted as a complex with the protein- latency-associated peptide (LAP). Tilos Therapeutics was founded by the collaboration of BI Venture Fund and Partners Innovation Fund
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com